Belgium· BE-AMP-SAM186462-00

Tasmar 100 mg

A tolcapone product containing tolcapone, registered in Belgium by Meda. The same ATC class is registered in 15 of our 19 countries.

ATC N04BX01

Checked against FAMHP / AFMPS (Belgium) on September 26, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about tolcaponeAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Tolcapone is registered in 15 of 19 countries.

Countries holding a registration under ATC N04BX01 (tolcapone), each read from that country’s own register.

This record: Belgium, from FAMHP / AFMPS (Belgium)
10 of them publish a price we can compare per daily dose

Search tolcapone products by name

Tolcapone · ATC N04BX01

15 / 19 countries

Belgiumprice
Czechiaprice
Denmark
Finlandprice
Franceprice
Germany
Icelandprice
Ireland
Italyprice
Netherlands
Norwayprice
Polandprice
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of tolcapone costs, country by country.

Normalised to the WHO defined daily dose (0.45 g), the median price runs from $6.12 in France to $9.92 in Switzerland — a ×1.6 gap.

3 markets with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Tolcapone · price per daily dose (0.45 g)

USD · FX 28 Sept 2026

CH Switzerland$9.92
IT Italy$8.47
FR France$6.12

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)

Active substance: Tolcapone
Manufacturer: Meda
Country: Belgium (BE)
ATC code: N04BX01
ATC class: Tolcapone
Defined daily dose: 0.45 g, O
Reimbursed: Not published by this register
Source register: FAMHP / AFMPS (Belgium)
Last checked: September 26, 2026

Packs & prices · 2

be_apb
1321504
be_apb
0781799

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

88 interactions on record for tolcapone.

Graded by severity as the source publishes them — 6 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check tolcapone against other medicines How interaction checks work

Tolcapone · interactions on record

88 records

6 severe
74 moderate
2 minor
6 info

Most severe, free to view

ProcarbazineL01XB01severe
LeflunomidL04AA13severe
TeriflunomidL04AA31severe
LeflunomideL04AK01severe

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Tolcapone in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All tolcapone products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

Germany · Tolcapon Neuraxpharm
Iceland · Tasmar
Liechtenstein · Tasmar
Norway · Tasmar

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/7765074a-da9f-4526-b64d-b83706d2e2ff
GET /v1/drugs/7765074a-da9f-4526-b64d-b83706d2e2ff?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Film-coated tablet",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Tasmar 100 mg",
  "name_fr": "Tasmar 100 mg",
  "name_nl": "Tasmar 100 mg",
  "amp_code": "SAM186462-00",
  "strengths": [
    "100.0000",
    "100.0000",
    "7.5000"
  ],
  "pack_count": 7,
  "substances": [
    "Tolcapone",
    "Lactose",
    "Sodium Laurilsulfate",
    "Sodium Starch Glycolate"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Tolcapone",
  "authorisation_numbers": [
    "EU/1/97/044/003",
    "EU/1/97/044/002",
    "EU/1/97/044/001",
    "EU/1/97/044/007",
    "EU/1/97/044/008",
    "EU/1/97/044/009",
    "EU/1/97/044/010"
  ]
}

API reference MCP server Plans

See everything about tolcapone.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console